Anti-glycation compositions and uses, conditioners

Abstract

The application discloses an anti-glycation composition and application and a conditioning agent. The anti-glycation composition comprises broccoli extract 40 μg / mL-102.4 g / mL, mangosteen extract 0.5 μg / mL-10 μg / mL and honeysuckle 10 μg / mL-30 μg / mL, wherein the honeysuckle comprises honeysuckle raw materials and / or honeysuckle extract. The application improves the synergistic effect among components by scientifically compounding three natural source components, i.e., broccoli extract, mangosteen extract and honeysuckle, so that the obtained composition can target inhibition of glycation and clearance of AGEs and CML, shows a significant anti-glycation effect, has a low use dose, high safety, has obvious advantages in the research and application of anti-glycation drugs, provides a safe and efficient new idea for delaying skin aging and preventing related diseases, and is suitable for being added into various anti-glycation functional products.

Description

Technical Field

[0001] This application relates to the field of biomedical technology, and in particular to anti-glycation compositions and their applications, and conditioning agents. Background Technology

[0002] In modern society, people are paying increasing attention to their health, and glycation is a significant factor affecting health. Reducing sugars (such as glucose) react with amino groups in proteins, lipids, and nucleic acids through a series of non-enzymatic reactions, including rearrangement, dehydration, oxidation, and condensation, ultimately forming stable and irreversible compounds called advanced glycation end products (AGEs). As endogenous AGEs formed during the physiological glycation process in human organs, tissues, and body fluids gradually accumulate in the body, excessive AGEs pose potential health risks and are associated with the pathogenesis of diabetic complications, Alzheimer's disease, and the normal aging process. Current anti-glycation products have limited efficacy, poor targeting of glycation reactions or AGEs, and require large dosages, raising concerns about safety. Therefore, finding functional active ingredients that can efficiently and safely inhibit glycation reactions and eliminate AGEs is crucial for developing effective anti-glycation products and is of great significance to human health. Summary of the Invention

[0003] Therefore, it is necessary to provide an anti-glycation composition that can effectively remove AGEs.

[0004] In a first aspect, this application provides an anti-glycation composition comprising 40 μg / mL-102.4 g / mL of broccoli extract, 0.5 μg / mL-10 μg / mL of mangosteen extract, and 10 μg / mL-30 μg / mL of houttuynia cordata, wherein the houttuynia cordata comprises houttuynia cordata raw material and / or houttuynia cordata extract.

[0005] In some embodiments, the anti-glycation composition comprises 60 μg / mL-102.4 μg / mL of broccoli extract, 0.5 μg / mL-2 μg / mL of mangosteen extract, and 15 μg / mL-30 μg / mL of houttuynia cordata extract.

[0006] In some embodiments, the anti-glycation composition comprises broccoli extract 90 μg / mL-102.4 μg / mL, mangosteen extract 1.2 μg / mL-1.6 μg / mL, and houttuynia cordata extract 20 μg / mL-30 μg / mL.

[0007] In some embodiments, the anti-glycation composition further satisfies at least one of the features shown in (1) to (3) below:

[0008] (1) The broccoli extract includes one or more of broccoli water extract and broccoli alcohol extract;

[0009] Optionally, the broccoli water extract includes broccoli seed water extract;

[0010] (2) The mangosteen extract includes one or more of mangosteen water extract and mangosteen alcohol extract;

[0011] (3) The houttuynia cordata is obtained by crushing houttuynia cordata raw material.

[0012] In some embodiments, the anti-glycation includes one or more of inhibiting glycation reactions, reducing carboxymethyl lysine levels, and reducing the content of advanced glycation end products.

[0013] Secondly, this application also provides a conditioning agent comprising the anti-glycation composition provided in the first aspect.

[0014] In some embodiments, the concentration of the anti-glycation composition in the conditioning agent is 30 μg / mL to 150 μg / mL.

[0015] In some embodiments, the conditioner also satisfies the characteristics shown in (1) and / or (2) below:

[0016] (1) The application methods of the conditioning agent include external use and / or internal use;

[0017] (2) The dosage forms of the conditioning agent include suspensions, granules, capsules, powders, tablets, emulsions, solutions, pellets, injections, aerosols, gels, patches, dressings, drops or liniments.

[0018] Thirdly, this application provides the use of a composition in the preparation of an anti-glycation product, the composition comprising broccoli extract, mangosteen extract and houttuynia cordata, wherein the houttuynia cordata comprises houttuynia cordata raw material and / or houttuynia cordata extract.

[0019] In some embodiments, the anti-glycation product further satisfies at least one of the features shown in (1) to (4) below:

[0020] (1) The composition comprises broccoli extract 40 μg / mL-102.4 g / mL, mangosteen extract 0.5 μg / mL-10 μg / mL and houttuynia cordata 10 μg / mL-30 μg / mL;

[0021] (2) The concentration of the composition in the anti-glycation product is 30 μg / mL to 150 μg / mL;

[0022] (3) The application methods of the anti-glycation products include external application and / or internal administration;

[0023] (4) The dosage forms of the anti-glycation products include suspensions, granules, capsules, powders, tablets, emulsions, solutions, pellets, injections, aerosols, gels, patches, dressings, drops or liniments.

[0024] Compared with traditional technologies, the technical solution of this application has the following advantages:

[0025] This application scientifically combines three naturally derived ingredients—broccoli extract, mangosteen extract, and houttuynia cordata—to fully leverage the advantages of each ingredient and enhance synergistic effects. The resulting composition significantly inhibits glycation, specifically targeting and suppressing AGEs and CML generated during the glycation process, or exogenous AGEs. It exhibits significant anti-glycation activity even at low doses, reducing the dosage of single-drug therapy and minimizing the risk of side effects. The technical solution presented in this application offers significant advantages in the research and application of anti-glycation drugs, providing a more effective, comprehensive, and safer treatment option for delaying skin aging and preventing related diseases. Detailed Implementation

[0026] To facilitate understanding of this application, preferred embodiments of this application are provided below for a more comprehensive description of the technical solutions of this application. However, this application can be implemented in many different forms and is not limited to the embodiments described herein. Rather, these embodiments are provided to enable a more thorough and complete understanding of the disclosure of this application.

[0027] It should be noted that experimental methods in the following embodiments of this application, unless otherwise specified, are generally performed under conventional conditions or as recommended by the manufacturer. All commonly used chemical reagents used in the embodiments are commercially available products.

[0028] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs. The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the application. The term "and / or" as used herein includes any and all combinations of one or more of the associated listed items.

[0029] The "range" disclosed in this application is defined by a lower limit and an upper limit. A given range is defined by selecting a lower limit and an upper limit, which define the boundaries of a particular range. Ranges defined in this way can include or exclude endpoints and can be arbitrarily combined; that is, any lower limit can be combined with any upper limit to form a range. For example, if ranges of 60-120 and 80-110 are listed for a specific parameter, it is expected that ranges of 60-110 and 80-120 are also included. Furthermore, if minimum range values ​​of 1 and 2 are listed, and if maximum range values ​​of 3, 4, and 5 are listed, then the following ranges are all expected: 1-3, 1-4, 1-5, 2-3, 2-4, and 2-5. In this application, unless otherwise stated, the numerical range "ab" represents a shortened representation of any combination of real numbers between a and b, where a and b are real numbers. For example, the numerical range "0-5" indicates that all real numbers between "0-5" have been listed in this document; "0-5" is simply a shortened representation of these numerical combinations. Furthermore, stating that a parameter is an integer ≥2 is equivalent to disclosing that the parameter is, for example, an integer 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, etc. For instance, stating that a parameter is an integer selected from "2-10" is equivalent to listing the integers 2, 3, 4, 5, 6, 7, 8, 9, and 10.

[0030] Unless otherwise specified, all embodiments and optional embodiments of this application can be combined to form new technical solutions.

[0031] Glycation refers to the non-enzymatic reaction between carbohydrates and biological macromolecules such as proteins and lipids to form advanced glycation end products (AGEs).

[0032] Advanced glycation end products (AGEs) are classified into endogenous and exogenous types based on their origin. Endogenous AGEs are formed during the physiological glycation process of human organs, tissues, and body fluids, while exogenous AGEs are formed during food processing due to the Maillard reaction. Both endogenous and exogenous AGEs accumulate in the human body, posing potential health risks. These risks include complications of diabetes, Alzheimer's disease, and the pathogenesis of normal aging processes, all of which are related to AGEs.

[0033] As people in modern society pay increasing attention to health and beauty, especially in anti-aging, anti-glycation products are gaining popularity. The accumulation of AGEs (Advanced Glycation End Products) is considered one of the main causes of skin aging, and carboxymethyl lysine (CML) is a major component of AGEs; its expression level can also serve as an important indicator of the degree of skin glycation. With age, collagen and elastin fibers in the skin gradually undergo glycation, leading to decreased skin elasticity, increased wrinkles, and dullness. Therefore, anti-glycation has become an important research direction in the fields of beauty and skin care. Finding drugs or preparations that can inhibit glycation is crucial for developing effective anti-aging products and helping to delay signs of aging such as wrinkles, sagging, and dullness.

[0034] Natural active substances have attracted much attention due to their abundant sources, good safety profile, and low toxicity. Developing anti-glycation functional products by obtaining effective active ingredients from natural products is a current and future trend. However, because the mechanisms of action of natural active substances are not fully understood, their efficacy is difficult to fully realize in application. Furthermore, the absorption and utilization rates of natural active substances are not high, leading to large dosages and potential side effects. Therefore, this application aims to find a class of natural active substances with anti-glycation effects, achieving synergistic effects through scientific formulation, and efficiently exerting anti-glycation activity within a low dosage range, thereby delaying aging and maintaining health.

[0035] In a first aspect, this application provides an anti-glycation composition comprising 40 μg / mL-102.4 g / mL of broccoli extract, 0.5 μg / mL-10 μg / mL of mangosteen extract, and 10 μg / mL-30 μg / mL of houttuynia cordata, wherein the houttuynia cordata comprises houttuynia cordata raw material and / or houttuynia cordata extract.

[0036] This application scientifically combines broccoli extract, mangosteen extract, and houttuynia cordata extract in specific proportions to produce a significant synergistic effect. This results in significant activities such as inhibiting glycation reactions and scavenging AGEs, demonstrating highly effective anti-glycation activity and improving the utilization rate of the raw materials. Furthermore, all three components are of natural origin and possess good biocompatibility and safety.

[0037] As a non-limiting example, the content of the broccoli extract in the composition of the anti-glycation composition includes, but is not limited to, 40 μg / mL, 45 μg / mL, 50 μg / mL, 51.2 μg / mL, 55 μg / mL, 60 μg / mL, 65 μg / mL, 70 μg / mL, 75 μg / mL, 80 μg / mL, 85 μg / mL, 90 μg / mL, 95 μg / mL, 100 μg / mL, 102.4 μg / mL, or any of the foregoing ranges and values ​​within those ranges. As a non-limiting example, the content of the mangosteen extract in the composition of the anti-glycation composition includes, but is not limited to, 0.5 μg / mL, 1 μg / mL, 1.5 μg / mL, 1.6 μg / mL, 2 μg / mL, 2.5 μg / mL, 3 μg / mL, 3.5 μg / mL, 4 μg / mL, 4.5 μg / mL, 5 μg / mL, 5.5 μg / mL, 6 μg / mL, 6.5 μg / mL, 7 μg / mL, 7.5 μg / mL, 8 μg / mL, 8.5 μg / mL, 9 μg / mL, 9.5 μg / mL, 10 μg / mL, or any of the foregoing ranges and values ​​within those ranges. As a non-limiting example, the content of Houttuynia cordata in the composition of the anti-glycation composition includes, but is not limited to, 10 μg / mL, 15 μg / mL, 20 μg / mL, 25 μg / mL, 30 μg / mL, or any range formed by both of the foregoing and values ​​within such ranges.

[0038] Furthermore, the anti-glycation composition comprises 60 μg / mL-102.4 μg / mL of broccoli extract, 0.5 μg / mL-2 μg / mL of mangosteen extract, and 15 μg / mL-30 μg / mL of houttuynia cordata extract.

[0039] Further, the anti-glycation composition comprises 90 μg / mL-102.4 μg / mL of broccoli extract, 1.2 μg / mL-1.6 μg / mL of mangosteen extract, and 20 μg / mL-30 μg / mL of houttuynia cordata. Even further, the anti-glycation composition comprises 102.4 μg / mL of broccoli extract, 1.6 μg / mL of mangosteen extract, and 30 μg / mL of houttuynia cordata.

[0040] In some embodiments, the broccoli extract includes substances extracted from the roots, branches, stems, leaves, seeds, and other parts of broccoli.

[0041] In some embodiments, the broccoli extract comprises one or more of broccoli aqueous extract and broccoli alcohol extract. As a non-limiting example, the broccoli alcohol extract comprises extraction using one or more alcohol solvents selected from methanol, ethanol, n-butanol, and isopropanol.

[0042] In some embodiments, the broccoli water extract includes broccoli seed water extract.

[0043] In some embodiments, the mangosteen extract comprises one or more of a water extract and an alcohol extract of mangosteen. As a non-limiting example, the alcohol extract of mangosteen is obtained by extraction using one or more alcohol solvents selected from methanol, ethanol, n-butanol, and isopropanol.

[0044] In some embodiments, the houttuynia cordata is obtained by pulverizing houttuynia cordata raw material.

[0045] In some embodiments, the anti-glycation includes one or more of inhibiting glycation reactions, reducing carboxymethyl lysine levels, and reducing the content of advanced glycation end products.

[0046] Secondly, this application also provides a conditioning agent comprising the anti-glycation composition provided in the first aspect.

[0047] In some embodiments, the concentration of the anti-glycation composition in the conditioner is 30 μg / mL to 150 μg / mL. This includes, but is not limited to, 30 μg / mL, 35 μg / mL, 40 μg / mL, 45 μg / mL, 50 μg / mL, 55 μg / mL, 60 μg / mL, 65 μg / mL, 70 μg / mL, 75 μg / mL, 80 μg / mL, 85 μg / mL, 90 μg / mL, 95 μg / mL, 100 μg / mL, 105 μg / mL, 110 μg / mL, 115 μg / mL, 120 μg / mL, 125 μg / mL, 130 μg / mL, 135 μg / mL, 140 μg / mL, 145 μg / mL, 150 μg / mL, or any range formed by both of the foregoing and values ​​within that range. Further, the concentration of the anti-glycation composition in the conditioner is 60 μg / mL to 150 μg / mL. In some embodiments, the concentration of the anti-glycation composition in the conditioner is 90 μg / mL to 150 μg / mL. Further, the concentration of the anti-glycation composition in the conditioner is 130 μg / mL to 150 μg / mL.

[0048] In some embodiments, the conditioning agent may be applied topically and / or orally.

[0049] In some embodiments, the dosage form of the conditioning agent includes suspensions, granules, capsules, powders, tablets, emulsions, solutions, pellets, injections, aerosols, gels, patches, dressings, drops, or liniments.

[0050] Thirdly, this application provides the use of a composition in the preparation of an anti-glycation product, the composition comprising broccoli extract, mangosteen extract and houttuynia cordata, wherein the houttuynia cordata comprises houttuynia cordata raw material and / or houttuynia cordata extract.

[0051] In some embodiments, as a non-limiting example, the content of the broccoli extract in the composition includes, but is not limited to, 40 μg / mL, 45 μg / mL, 50 μg / mL, 51.2 μg / mL, 55 μg / mL, 60 μg / mL, 65 μg / mL, 70 μg / mL, 75 μg / mL, 80 μg / mL, 85 μg / mL, 90 μg / mL, 95 μg / mL, 100 μg / mL, 102.4 μg / mL, or any range formed by both of the foregoing and values ​​within such ranges. As a non-limiting example, the content of the mangosteen extract in the composition includes, but is not limited to, 0.5 μg / mL, 1 μg / mL, 1.5 μg / mL, 1.6 μg / mL, 2 μg / mL, 2.5 μg / mL, 3 μg / mL, 3.5 μg / mL, 4 μg / mL, 4.5 μg / mL, 5 μg / mL, 5.5 μg / mL, 6 μg / mL, 6.5 μg / mL, 7 μg / mL, 7.5 μg / mL, 8 μg / mL, 8.5 μg / mL, 9 μg / mL, 9.5 μg / mL, 10 μg / mL, or any combination thereof, and values ​​within that range. As a non-limiting example, the content of houttuynia cordata in the composition includes, but is not limited to, 10 μg / mL, 15 μg / mL, 20 μg / mL, 25 μg / mL, 30 μg / mL, or any combination thereof, and values ​​within that range.

[0052] Further, the composition comprises 60 μg / mL-102.4 μg / mL of broccoli extract, 0.5 μg / mL-2 μg / mL of mangosteen extract, and 15 μg / mL-30 μg / mL of houttuynia cordata. Further, the composition comprises 90 μg / mL-102.4 μg / mL of broccoli extract, 1.2 μg / mL-1.6 μg / mL of mangosteen extract, and 20 μg / mL-30 μg / mL of houttuynia cordata. Even further, the composition comprises 102.4 μg / mL of broccoli extract, 1.6 μg / mL of mangosteen extract, and 30 μg / mL of houttuynia cordata.

[0053] In some embodiments, the concentration of the composition in the anti-glycation product is 30 μg / mL to 150 μg / mL. This includes, but is not limited to, 30 μg / mL, 35 μg / mL, 40 μg / mL, 45 μg / mL, 50 μg / mL, 55 μg / mL, 60 μg / mL, 65 μg / mL, 70 μg / mL, 75 μg / mL, 80 μg / mL, 85 μg / mL, 90 μg / mL, 95 μg / mL, 100 μg / mL, 105 μg / mL, 110 μg / mL, 115 μg / mL, 120 μg / mL, 125 μg / mL, 130 μg / mL, 135 μg / mL, 140 μg / mL, 145 μg / mL, 150 μg / mL, or any range formed by both of the foregoing and values ​​within that range. Further, the concentration of the composition in the anti-glycation product is 60 μg / mL to 150 μg / mL. In some embodiments, the concentration of the composition in the anti-glycation product is 90 μg / mL to 150 μg / mL. Further, the concentration of the composition in the anti-glycation product is 130 μg / mL to 150 μg / mL.

[0054] In some embodiments, the anti-glycation product may be applied topically and / or orally.

[0055] In some embodiments, the dosage form of the anti-glycation product includes suspensions, granules, capsules, powders, tablets, emulsions, solutions, pellets, injections, aerosols, gels, patches, dressings, drops, or liniments.

[0056] As a non-limiting example, the oral anti-glycation products include anti-glycation oral liquids and anti-glycation beverages, etc.

[0057] As a non-limiting example, the topical anti-glycation products include face masks, toners, serums, essences, foundations, and creams.

[0058] For experimental parameters not specified in the following specific embodiments, please refer to the guidelines given in this application document first, or refer to experimental manuals or other experimental methods known in the art, or refer to the experimental conditions recommended by the manufacturer.

[0059] The raw materials and reagents involved in the following specific embodiments can be obtained commercially or prepared by those skilled in the art using known methods.

[0060] The specific sources and types of raw materials and cells involved in the specific embodiments of this application are as follows:

[0061] Broccoli seed water extract, product number 60202003, was purchased from Ganzhou Huahan Biotechnology Co., Ltd.; mangosteen extract was purchased from Shinyaku Co., Ltd., Japan; houttuynia cordata powder was purchased from Betalife (Tianjin) Biotechnology Co., Ltd.

[0062] All other chemical reagents are conventional reagents.

[0063] Example 1: Anti-glycation composition and its preparation method

[0064] The anti-glycation composition formulation provided in this embodiment is as follows:

[0065] Formula 1: Broccoli seed water extract 50 μg / mL + mangosteen extract 10 μg / mL + houttuynia cordata powder 10 μg / mL.

[0066] Formula 2: Broccoli seed water extract 60 μg / mL + mangosteen extract 0.5 μg / mL + houttuynia cordata powder 10 μg / mL.

[0067] Formula 3: Broccoli seed water extract 40 μg / mL + mangosteen extract 5 μg / mL + houttuynia cordata powder 25 μg / mL.

[0068] Formula 4: Broccoli seed water extract 55 μg / mL + mangosteen extract 0.5 μg / mL + houttuynia cordata powder 15 μg / mL.

[0069] Formula 5: Broccoli seed water extract 51.2 μg / mL + mangosteen extract 0.8 μg / mL + houttuynia cordata powder 15 μg / mL.

[0070] Formula 6: Broccoli seed water extract 102.4 μg / mL + mangosteen extract 1.6 μg / mL + houttuynia cordata powder 30 μg / mL.

[0071] The above six formulations were prepared by mixing them with complete cell culture medium according to the formulation amounts.

[0072] All three formulations described above have anti-glycation effects.

[0073] Comparative Example 1: Composition and its preparation method

[0074] Formula 7: Broccoli seed water extract 57 μg / mL + mangosteen extract 10 μg / mL.

[0075] Formula 8: Broccoli seed water extract 52 μg / mL + Houttuynia cordata powder 15 μg / mL.

[0076] Formula 9: Mangosteen extract 10μg / mL + Houttuynia cordata powder 15μg / mL.

[0077] The above three formulations were prepared by mixing them with complete cell culture medium according to the specified formulation amounts.

[0078] Experimental Example 1: Effects of Drugs on Cell Viability

[0079] HACAT cells (purchased from Zhejiang Meisen Cell Technology Co., Ltd.) were seeded in 96-well plates at a density of 11,000 per well and incubated in a 5% CO2, 37°C constant temperature cell culture incubator until the cell density reached more than 80%. Different concentrations of drugs were then used for stimulation, and the cells were incubated again for 24 hours. Cell status was observed and cell viability was measured. ATP was measured at 6 concentrations for each monomeric drug. Cell viability below 90% indicates that the drug is toxic to HACAT cells.

[0080] The experiment used the CeLLTiter-GLo® cell viability assay kit (purchased from Promega, catalog number G9242) to detect the number of viable cells by measuring ATP. Following the instructions, the original culture medium in the 96-well plate was discarded, and 100 μL of ATP reagent was added directly without washing the cells. The plate was incubated at 37°C for 20 min, and ATP was measured using a microplate reader. The cell viability was calculated using formula (1).

[0081] (1)

[0082] The concentrations of the single drug in this experiment are shown in Table 1:

[0083] Table 1: Single Drug Concentration

[0084]

[0085] Based on the drug concentrations in Table 1, the specific experimental results of cellular ATP activity measured using the above testing methods are shown in Table 2:

[0086] Table 2: Cell viability of single drugs and combinations

[0087]

[0088] As shown in Table 2, all single drugs showed no toxicity to HACAT cells at low concentrations. However, as the concentration increased, the drugs exhibited different toxic effects on HACAT cells. All formulations showed no toxicity.

[0089] Experimental Example 2: Effects of Drugs on GLA-Induced Glycation of HACAT Cells

[0090] This experiment successfully constructed a glycation model on skin epidermal cells using glyceraldehyde (GLA). Glyceraldehyde is a reducing sugar with a faster glycation rate than glucose, allowing for the observation of glycation effects in a shorter time. It is also relatively stable in cell culture environments and not easily metabolized by cells. As a reagent that can replace high-concentration glucose in constructing cellular glycation models, glyceraldehyde can improve the efficiency and accuracy of experiments while reducing potential cell damage. This provides a more ideal method for studying skin glycation and offers an important experimental basis for investigating the skin glycation process and screening anti-glycation drugs.

[0091] The specific experimental steps were as follows: 750,000 HACAT cells were seeded in 6cm cell culture dishes and incubated at 37°C with 5% CO2 until the cell density reached over 70%. A glycation model was established by stimulation with 700μM GLA. Simultaneously, single-drug and compound-drug combinations were added to the culture dishes (with a blank control group without GLA or drugs). After 24 hours of incubation, the medium was changed, and the cells were cultured again for 24 hours. Cell samples were then collected. Cells were scraped off using a cell scraper and collected in 15mL centrifuge tubes. The tubes were centrifuged at 4000rpm for 5 minutes, the supernatant was discarded, and 500μL of RIPA lysis buffer was added. The cells were lysed on ice for 20 minutes, centrifuged at 13000rpm for 10 minutes, and the supernatant was used as the sample. A portion was used for BCA total protein quantification, and the remainder was analyzed using a CML kit. The human carboxymethyl lysine (CML) and human advanced glycation end products (AGEs) ELISA kits used in the experiment were both purchased from Wuhan Huamei Biotechnology Co., Ltd. Specific procedures were followed according to the instruction manual. The results are shown in Tables 3 and 4.

[0092] Table 3: Effects of various drugs on CML formation after cell glycosylation ( ±s, n=3)

[0093]

[0094] As shown in Table 3, the results of CML determination of single drugs showed that broccoli water extract, mangosteen extract and houttuynia cordata powder inhibited CML formation in the GLA-induced HACAT glycation model. Formulas 1 to 6 had a more significant inhibitory effect than formulas 7 to 9, indicating that the present application achieved a synergistic effect through the scientific combination of the three components, and formula 6 had a more significant anti-glycation effect than the other formulas.

[0095] Table 4: Effects of various drugs on AGEs formation after cell glycosylation ( ±s, n=3)

[0096]

[0097] The results in Table 4 show that the combination of the three components within a specific ratio range can significantly inhibit the production of AGEs in HaCaT cells, and the combinations of formulas 1 to 6 are more effective than those of formulas 7 to 9.

[0098] The anti-glycation composition provided in this application exhibits superior anti-glycation efficacy compared to single-agent drugs, particularly targeting key indicators such as AGEs and CML with clearly defined action points. This makes anti-glycation treatment more targeted, maintaining or enhancing anti-glycation effects while reducing the dosage of each single-agent drug, thereby lowering the risk of side effects and improving anti-glycation efficacy. The technical solution of this application has significant advantages in the research and application of anti-glycation drugs. The anti-glycation composition provided in this application offers new ideas and methods for delaying skin aging and preventing related diseases. Furthermore, the glycation model constructed using glyceraldehyde provides a more stable and reliable experimental platform for the efficient screening of anti-glycation active ingredients.

[0099] The technical features of the above embodiments can be combined in any way. For the sake of brevity, not all possible combinations of the technical features in the above embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0100] The embodiments described above are merely illustrative of several implementation methods of this application, and while the descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the invention patent. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of this application, and these all fall within the protection scope of this application. Therefore, the protection scope of this patent application should be determined by the appended claims.

Claims

1. An anti-glycation composition, characterized in that, The anti-glycation composition comprises 90 μg / mL-102.4 g / mL of broccoli seed water extract, 1.2 μg / mL-1.6 μg / mL of mangosteen extract, and 20 μg / mL-30 μg / mL of houttuynia cordata extract; the mangosteen extract includes one or more of mangosteen water extract and mangosteen alcohol extract; the houttuynia cordata is obtained by pulverizing houttuynia cordata raw material.

2. The anti-glycation composition according to claim 1, characterized in that, The anti-glycation method includes one or more of the following: inhibiting glycation reactions, reducing carboxymethyl lysine levels, and reducing the content of advanced glycation end products (AGEs).

3. A conditioning agent, characterized in that, The conditioning agent includes the anti-glycation composition according to any one of claims 1 to 2.

4. The conditioner according to claim 3, characterized in that, The concentration of the anti-glycation composition in the conditioning agent is 30 μg / mL to 150 μg / mL.

5. The conditioner according to claim 3, characterized in that, The conditioner also satisfies the following characteristics as shown in (1) and / or (2): (1) The application of the conditioning agent includes external or internal use; (2) The dosage forms of the conditioning agent include suspensions, granules, capsules, powders, tablets, emulsions, solutions, pellets, injections, aerosols, gels, patches, dressings, drops or liniments.

6. The application of the composition in the preparation of anti-glycation products, characterized in that, The composition comprises 90 μg / mL-102.4 g / mL of broccoli seed water extract, 1.2 μg / mL-1.6 μg / mL of mangosteen extract, and 20 μg / mL-30 μg / mL of houttuynia cordata extract; the mangosteen extract includes one or more of mangosteen water extract and mangosteen alcohol extract; the houttuynia cordata extract is obtained by pulverizing houttuynia cordata raw material.

7. The use of the composition according to claim 6 in the preparation of anti-glycation products, characterized in that, The anti-glycation product also satisfies at least one of the following features (1) to (3): (1) The concentration of the composition in the anti-glycation product is 30 μg / mL to 150 μg / mL; (2) The application methods of the anti-glycation products include external use or internal use; (3) The dosage forms of the anti-glycation products include suspensions, granules, capsules, powders, tablets, emulsions, solutions, pellets, injections, aerosols, gels, patches, dressings, drops or liniments.

Images